Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05269862 · ClinicalTrials.gov registry record · NA

Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation

A NA study of Parkinson Disease, sponsored by Abbott Medical Devices.

Active
Registry status
NA
Development phase
100
Enrollment target
18
Study locations

NCT05269862: Active NA study of Parkinson Disease, sponsored by Abbott Medical Devices.

NCT05269862 is a NA study of Parkinson Disease that is active but no longer recruiting, run by Abbott Medical Devices. The registered enrollment target is 100 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 18 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05269862, a NA study of Parkinson Disease, is active but no longer recruiting, sponsored by Abbott Medical Devices.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
18
Study locations

Study Summary

The purpose of the ROAM-DBS study is to compare the time needed to achieve a 1 point improvement Patient's Global Impression of change (PGIC) relative to the subject's status at the end of the ADROIT initial programming visit in subjects who receive programming updates via in-clinic sessions and subjects who additionally have the option of receiving programming updates via Virtual Clinic sessions. The study intends to demonstrate shorter times to achieve benefit in the Virtual Clinic cohort.

Primary Outcome

The PGI consists of 2 subscales, the first rating the severity of illness (PGIS) and the second evaluating the change in illness relative to a previous status (PGIC). The PGI scale evaluates all aspects of health and assesses if there has been a change in clinical status. The scale consists of two items, one scale rating severity of illness and one rating global improvement. Severity is rated from 1=normal/not at all ill to 7= extremely ill. Global improvement is rated from 1=very much improved

Conditions Studied

Interventions

  • DEVICE Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature
  • DEVICE Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)

Study Locations (18)

Other

  • Hospital Universitari Germans Trias I Pujol - Badalona
  • Hospital Universitario de la Princesa - Madrid
  • Hospital Virgen de Rocio - Seville

Ohio

  • The Cleveland Clinic Foundation - Cleveland
  • Ohio State Medical - Columbus

Arizona

  • University of Arizona Health Sciences Center - Tucson

California

  • University of California at Davis - Sacramento

Florida

  • University of Miami Hospital - Miami

Illinois

  • Rush University Medical Center - Chicago

Indiana

  • Indiana University - Indianapolis

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2022-03-24
Est. Completion 2024-12
Phase NA
Abbott Medical Devices

261 total trials

What the registry record for NCT05269862 still lists

NCT05269862 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature is the first listed.

NCT05269862 lists 18 locations in 15 states (Other, Ohio, Arizona).

Frequently Asked Questions

What is clinical trial NCT05269862 about?

NCT05269862 is a clinical study titled "Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation". The purpose of the ROAM-DBS study is to compare the time needed to achieve a 1 point improvement Patient's Global Impression of change (PGIC) relative to the subject's status at the end of the ADROIT initial programming visit in subjects who receive programming updates via in-clinic sessions and sub...

What is the current status of trial NCT05269862?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2022-03-24. Estimated completion is 2024-12.

What conditions does trial NCT05269862 study?

This clinical trial studies the following conditions: Parkinson Disease.

What interventions are being tested in trial NCT05269862?

The interventions under investigation include: Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (DEVICE), Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions) (DEVICE).

Who is sponsoring clinical trial NCT05269862?

This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05269862 being conducted?

This trial has 18 study locations across Arizona, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05269862's enrollment target sits among peer trials

100 86th of 297 higher than 207 of 297 other Parkinson Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05269862, the US trial registry maintained by the National Library of Medicine. NCT05269862 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.